{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:59:18Z","timestamp":1787731158192,"version":"build-2784847793"},"reference-count":42,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.2217\/fon-2021-0805","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T10:26:26Z","timestamp":1643019986000},"page":"1499-1510","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Analytical Similarity as Base for Rituximab Biosimilars in Lymphoid Malignancies in the Clinic: A PF-05280586 Case Study"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-6115","authenticated-orcid":false,"given":"Jeff P","family":"Sharman","sequence":"first","affiliation":[{"name":"Willamette Valley Cancer Institute & Research Center, US Oncology,  \rEugene, OR97401, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol F","family":"Kirchhoff","sequence":"additional","affiliation":[{"name":"Pfizer Inc.,  \r\rChesterfield, MO63017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers, US Oncology Research,  \rDenver, CO80218, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075027"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9151-8_1"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.57"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802917"},{"key":"e_1_3_3_8_1","first-page":"CD007356","article-title":"Rituximab for rheumatoid arthritis","volume":"1","author":"Lopez-Olivo MA","year":"2015","unstructured":"Lopez-Olivo MA , AmezagaUrruela M, McGahanL, PollonoEN, Suarez-AlmazorME. Rituximab for rheumatoid arthritis. Cochrane Database Syst. Rev.1, CD007356 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3762864"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1665017"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01193-y"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000192"},{"key":"e_1_3_3_13_1","article-title":"Ruxience (rituximab)","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency . Ruxience (rituximab). Summary of Product Characteristics (2020). www.ema.europa.eu\/en\/documents\/product-information\/ruxience-epar-product-information_en.pdf","journal-title":"Summary of Product Characteristics"},{"key":"e_1_3_3_14_1","article-title":"Ruxience (rituximab)","author":"US Food and Drug Administration","year":"2019","unstructured":"US Food and Drug Administration . Ruxience (rituximab). Prescribing Information (2019). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761103s000lbl.pdf","journal-title":"Prescribing Information"},{"key":"e_1_3_3_15_1","unstructured":"US Food and Drug Administration . Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. (2015). www.fda.gov\/media\/82647\/download"},{"key":"e_1_3_3_16_1","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) . Guideline on similar biological medicinal products (2014). www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf"},{"key":"e_1_3_3_17_1","unstructured":"US Food and Drug Administration . Biosimilar development review and approval (2017). www.fda.gov\/drugs\/biosimilars\/biosimilar-development-review-and-approval"},{"key":"e_1_3_3_18_1","unstructured":"European Medicines Agency . Biosimilar medicines: marketing authorisation (2019). www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/biosimilar-medicines-marketing-authorisation"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02953"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0218-5"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150971"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10295-019-02216-z"},{"key":"e_1_3_3_23_1","unstructured":"US Food and Drug Administration . Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product guidance for industry (2015). www.fda.gov\/media\/135612\/download"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0230-9"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/273086"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/B978-0-12-374984-0.01203-1","volume-title":"Brenner\u2019s Encyclopedia of Genetics, 2nd Edition.","author":"Uversky VN","year":"2013","unstructured":"Uversky VN . Posttranslational modification. In: Brenner\u2019s Encyclopedia of Genetics, 2nd Edition.MaloyS, HughesK (Eds). Academic Press, Amsterdam, The Netherlands, 425\u2013430 (2013)."},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.26438"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwv065"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.05.028"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21566"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.21328"},{"key":"e_1_3_3_32_1","unstructured":"World Health Organization . Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs) (2016). www.who.int\/biologicals\/expert_committee\/mAb_SBP_GL-ECBS_review_adoption-2016.10.26-11.7post_ECBS-Clean_Version.pdf"},{"key":"e_1_3_3_33_1","unstructured":"US Food and Drug Administration . Q8(R2) pharmaceutical development (2009). www.fda.gov\/downloads\/drugs\/guidances\/ucm073507.pdf"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.104415"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00398-7"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12916"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S190784"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-001230"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1039\/C4AN01806K"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0192623313520351"},{"key":"e_1_3_3_41_1","article-title":"Ruxience","author":"US Food and Drug Administration","year":"2019","unstructured":"US Food and Drug Administration . Ruxience. Product Quality Review (2019). www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761103Orig1s000ChemR.pdf","journal-title":"Product Quality Review"},{"key":"e_1_3_3_42_1","article-title":"Ruxience","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency . Ruxience. Assessment Report (2020). www.ema.europa.eu\/en\/documents\/assessment-report\/ruxience-epar-public-assessment-report_en.pdf","journal-title":"Assessment Report"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0066"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0131"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-0805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:49Z","timestamp":1719125149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-0805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.2217\/fon-2021-0805"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-0805","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}